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ABSTRACT There is increasing evidence demonstrating an association between chronic obstructive
pulmonary disease (COPD) and cognitive impairment. We present a narrative review of published studies
on the subject and a cross-sectional study investigating domain-specific cognitive impairment in people
with COPD compared to people with known Alzheimer’s dementia, and controls without known COPD
or cognitive impairment. The aim of the study was to compare prevalence and pattern of cognitive
impairment between the three groups using the Addenbrooke’s Cognitive Examination (ACE)-III tool.
A total of 89 participants were recruited (44 with COPD, 17 with Alzheimer’s and 28 controls).
Patients with COPD had significantly lower total ACE-III scores than controls (p<0.001). When
comparing the COPD group to the known Alzheimer’s dementia group, overall ACE-III scores were
significantly lower in the Alzheimer’s dementia group than the COPD group (p=0.019). The domain-
specific scores for attention (p<0.004), memory (p<0.004) and fluency (p<0.001) were significantly lower
in the Alzheimer’s dementia group than the COPD group.
Our result suggest that the COPD group were significantly more likely to have cognitive impairment
than the healthy control group. This was supported by the results of a narrative review of the published
literature. Our results show that the pattern of impairment in the COPD group is different to the pattern
of impairment shown in the known Alzheimer’s dementia group, with significant differences in the
cognitive domains affected. These results are in keeping with the findings of other previously published
studies included in the narrative review.
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People with COPD are more likely than controls to have cognitive impairment. When compared
to people with known Alzheimer’s disease, the pattern of impairment and cognitive domains
affected are significantly different. http://bit.ly/2VPFxjh
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ORIGINAL ARTICLE
COPD
Introduction
The typical profile of patients with chronic obstructive pulmonary disease (COPD) includes a wide range
of comorbidity. There is increasing evidence demonstrating an association between COPD and cognitive
impairment [1–3]. With an ageing population and the consequent rise in the prevalence of cognitive
impairment, this is a topical area of research needing further investigation, particularly in terms of the
domains of cognition affected in COPD patients. Prevalence estimates of cognitive impairment in COPD
in previously reported studies vary widely, ranging from 2% to 52%; how this compares to age-matched
controls is unclear. A number of suggestions have been made regarding the underlying pathophysiology,
including cerebral hypoxia, loss of hippocampal volume and inflammatory mediator-related neuronal
damage [2, 4].
There is suggestion that people with COPD have different areas of cognitive ability affected than those
diagnosed with Alzheimer’s dementia or other known types of dementia [1–4]. If confirmed, this would be
clinically relevant for COPD management (e.g. it might alter the ability to comply with particular
treatment types or benefit from more complex therapies) and for care of their comorbid disease, as specific
types of cognitive impairment may have different management strategies [5]. What is unclear is if there is
a specific type of neurocognitive dysfunction related to COPD and little literature relates to the direct
investigation of this.
This article presents a literature review that examines the peer-reviewed, published literature regarding the
link between COPD and cognitive impairment, specifically examining evidence for a discrete type of
impairment in those with COPD, and its mediating factors. The narrative conclusions from the review of the
literature led to our conducting a cross-sectional study investigating domain-specific cognitive impairment in
people with COPD compared to patients with known Alzheimer’s-type dementia and healthy controls
without known COPD or cognitive impairment, the results of which are also reported here. The aim was to
compare the prevalence and pattern of cognitive impairment between the three groups.
Methods
Literature review
A comprehensive search was performed of the PubMed database and the Cochrane Database of Systematic
Reviews for papers published between January 2010 and January 2015 concerning cognition and COPD.
Table 1 summarises inclusion criteria. References from previous systematic reviews prior to 2010 were
extracted. Standard methods to eliminate bias were employed. Two reviewers examined retrieved titles and
abstracts, and where appropriate, manuscripts. Papers included after the title/abstract stage were read by
two authors (H-C. Younan and C. Morris) and reviewed for inclusion. Studies were reviewed to determine
“themes” of clinical or mechanistic relevance, with a view to meta-analysis. Since study heterogeneity
precluded this, narrative conclusions and comparisons became the focus of our output. Further details on
review methodology are detailed in the supplementary material.
Methods for cross-sectional study
Participants
We enrolled patients with moderate to severe COPD from a secondary care respiratory clinic in a
medium-sized urban teaching hospital in the UK over an 8-month study period from June 2016 to April
2017. Moderate to severe COPD was defined as patients with a forced expiratory volume in 1 s (FEV1) of
<80% predicted.
TABLE 1 Criteria for inclusion in the review
Study designs Clinical trials, epidemiological studies, observational studies, cohort studies, review
articles or case–control studies exploring a direct link between COPD and cognitive
impairment
Patients Patients diagnosed with COPD
Intervention Cognitive testing using various cognitive testing tools, including domain-specific
cognitive tools
Comparator Patients without known/diagnosed COPD
Outcomes Cognitive impairment as defined by the specified tools used in the individual studies
Domains of cognition affected/domain specific scores on the cognitive testing tools
COPD: chronic obstructive pulmonary disease.
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As a comparator, patients with known cognitive impairment and a formal diagnosis of Alzheimer’s
dementia but without COPD were recruited from the Join Dementia Research Network. Control patients
with a similar age profile and sex distribution but without a diagnosis of COPD or cognitive impairment
were also recruited.
All subjects gave their informed, written consent in accordance with the Declaration of Helsinki and
following approval from the National Health Service Local Research Ethics Committee (ref. 16/EM/0192)
Assessment of cognition
We used the Addenbrookes Cognitive Examination (ACE)-III to assess cognitive impairment. The ACE-III
is a validated tool that can be used to establish areas of cognition affected in different types of dementias [6].
Cut-off scores for possible dementia and mild cognitive impairment are 82 and 88 out of 100, respectively.
The ACE-III investigates six different domains of cognition: memory, attention, perception, visuospatial
abilities, language and verbal fluency.
In a subgroup, data regarding baseline oxygen saturations, FEV1 and FEV1 % pred values were available.
Data regarding FEV1 and FEV1 % pred were available for 29 participants (28 in the COPD group and one
control). Data for baseline oxygen saturations were available for 28 participants (27 in the COPD group
and one control). We completed further analysis comparing overall and domain-specific scores compared
to baseline oxygen saturations, FEV1 and FEV1 % pred.
Statistical analysis
All statistical analyses were carried out in SPSS version 25 (IBM, Armonk, NY, USA). We analysed the
difference in ACE-III total and domain-specific scores between groups. Dunn’s pairwise tests were then
carried out for two pairs of groups (COPD group compared to cognitive impairment group and COPD
group compared to control group) for each analysis. The significance values were then adjusted using
Bonferroni corrections, given multiple group comparisons.
ANOVA was then performed to control for cardiovascular disease (CVD) and smoking. A Dunnet’s
pairwise multicomparison test was then performed to compare the COPD and cognitive impairment
group and the COPD and control group. We used linear regression with Pearson’s correlation coefficient
and Spearman rank correlation to compare the baseline saturations, FEV1 and FEV1 % pred data to overall
and domain-specific ACE-III scores.
Results
Results of narrative review
We retrieved 327 original articles of which 18 met the inclusion criteria. A further 94 were retrieved from
the reference list of a prior systematic review of which 13 were included; 31 met the inclusion criteria for
the final review. Table 2 describes summary characteristics of the included studies and major findings (see
the supplementary material for detail and a Preferred Reporting Items for Systematic Reviews and
Meta-Analyses diagram).
The included studies did not specify the type of dementia or major neurocognitive disorder present in
subjects and rarely specified if dementing conditions with a known pathophysiology (such as alcoholic
dementia) were excluded. The 31 included papers employed psychometric tests to establish the level of
impairment in cognition and domains affected, but did not translate the results of these cognitive tests
into clinical diagnoses. As different studies used different psychometric tests the definition of cognitive
impairment was not standardised and differed in the different papers included in the review.
Four papers studied cognitive outcomes according to COPD severity [7–10]. However, one of these papers
used “self-reported history of COPD” rather than pulmonary function testing to classify COPD severity [10].
Varying criteria were used to diagnose COPD in the included studies. These variations in definitions and
methodological limitations affected the quality of included studies and the inferences that can be made,
although it seemed cognitive impairment was increased in COPD patients and largely affected memory.
10 of the studies included in the review discussed effects of hypoxia or hypoxaemia on cognitive
impairment, with two concluding that there is a relationship between arterial oxygen tension (PaO2) and
severity of cognitive impairment [7, 11]. Reduced PaO2 particularly related to impairment in the areas of
motor function, attention and processing speed. However, this association was inconsistent; DODD et al. [1]
found that cognitive function was only mildly impaired in patients without hypoxaemia. ANTONELLI-INCALZI
et al. [12] included hypoxic–hypercapnic COPD cases and found that 48.5% had a form of cognitive
deterioration; longer duration of hypercapnia and hypoxia was significantly correlated to cognitive
impairment. Other mechanisms were considered by included studies; however, there was relatively little
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consistency to the findings (supplementary material). Since the review findings were somewhat limited, we
felt validation work was necessary, which comprised the second part of our study.
Cross-sectional study
A total of 89 participants were recruited over the study period (44 with COPD, 17 with Alzheimer’s and
28 controls). Recruitment was challenging, particularly for the known Alzheimer’s dementia group,
eventually resulting in use of a national network to enhance case ascertainment. Comparison of baseline
characteristics demonstrated no significant difference between the three groups except for smoking
exposure >10 pack-years and cardiovascular comorbidity, which were more frequently observed in the
COPD group (table 3).
Patients with COPD had significantly lower total ACE-III scores compared to the healthy controls
(p<0.001). 50% (95% CI 33.8–66.2%) of COPD patients demonstrated scores below the cut-off for
cognitive impairment (88 out of 100). This compares to just 7% (95% CI 9.0–23.5%) of healthy control
group participants. The distribution of total ACE-III scores is presented in figure 1.
Domain-specific scores
In patients with COPD, memory and fluency subscores were significantly lower compared to healthy
control group participants whilst other cognitive domains remained intact. Whilst patients with COPD
had lower total ACE-III scores compared to healthy controls (COPD group median 87.5 (interquartile
range (IQR) 84–91) versus control group median 96 (IQR 93–97)) scores were significantly higher than for
patients in the known Alzheimer’s dementia group (median 79, IQR 70–80).
There were significant differences in the overall ACE-III scores (p=0.019) and in the attention (p=0.004),
memory (p=0.004) and fluency subscores (p<0.001) between the COPD group and the known Alzheimer’s
dementia group. Those with COPD scored significantly higher overall and in these domains.
TABLE 2 Characteristics and findings of included studies
Number of patients
COPD 11171
Other forms of cognitive impairment diagnosed prior to inclusion 46
Controls 48689
Age years mean 67.53
Cognitive impairment instruments used in more than one study
Halstead-Reitan Test Battery 3
Wechsler Adult Intelligence Scale 3
Mental Deterioration Battery 3
Trail Making Test A-D 7
Wechsler Test of Adult Reading 2
Mini Mental State Examination 14
Wechsler Memory Scale-III test battery 5
Grooved pegboard test 2
Seashore Rhythm Test 3
Study design
Cohort 7
Case–control 14
Observational 2
Cross-sectional 2
Interventional 1
Review articles (not included in table) 5
Studies reporting COPD and cognitive impairment
An association between COPD and cognitive impairment 20
No association 2
Studies with statistically significant differences seen in COPD#
Memory 5
Attention 3
Fluency 4
Language 2
Visuospatial 3
COPD: chronic obstructive pulmonary disease. #: not all included studies reported domain-specific results.
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Lower baseline saturations were significantly correlated with lower overall scores in the domain of fluency
(p<0.01). Baseline saturations were not correlated with overall ACE-III score or with any of the other
cognitive domains. Lower FEV1 was correlated with lower ACE-III scores in the domains of memory
(p=0.03) and fluency (p=0.04) but not overall ACE-III score (tables 4–6).
Discussion
Studies included in the review demonstrated increased prevalence of cognitive impairment in COPD
patients compared to controls but the quality and heterogeneity of studies limited conclusions that could
be drawn. Particularly important was that diagnosis of cognitive symptoms was rarely precise. It was
TABLE 3 Demographic and clinical characteristics
COPD
(n=44)
Known AD
(n=17)
Healthy
controls
(n=28)
Test statistic Significance
Age years 72 (68–77) 79 (70–80) 71.5 (69–74) H=4.1 p=0.13
Females 23 (52%) 6 (35%) 13 (46%) χ2=1.4 p=0.49
Smoking history >10 pack-years 41 (93%) 5 (29%) 5 (18%) χ2=46.4 p<0.01
>14 units alcohol per week 7 (16%) 2 (12%) 8 (29%) χ2=2.51 p<0.28
CVD diagnosis 17 (38%) 6 (35%) 3 (11%) χ2=8.51 p=0.01
Diabetes mellitus diagnosis 5 (11%) 2 (12%) 3 (11%) FET p=0.99
COPD subgroup analysis
FEV1 % predicted mean 45
Oxygen saturation mean 90.4%
COPD Known AD Healthy
controls
COPD–control
comparison#
COPD–known AD
comparison#
ACE-III total¶ score 87.5 (84–91) 73 (69–85) 96 (93–97) p<0.001 p=0.019
Attention subscore+ 17 (16–18) 15 (13–17) 18 (18–18) p=0.090 p=0.004
Memory subscore§ 21 (20–24) 14 (11–18) 25 (25–26) p<0.001 p=0.004
Fluency subscoreƒ 10 (8–12) 8 (6–10) 12 (10–13) p=0.017 p<0.001
Language subscore## 25 (23–26) 24 (21–25) 26 (25–26) p=0.100 p=0.100
Visuospatial subscore¶¶ 15 (14–16) 15 (14–16) 16 (15–16) p=0.096 p=0.096
Data are presented as median (interquartile range) unless otherwise stated. Chi-squared tests were performed with two degrees of freedom.
COPD: chronic obstructive pulmonary disease; AD: Alzheimer’s dementia; IQR: interquartile range; CVD: cardiovascular disease; FEV1: forced
expiratory volume in 1 s; ACE: Addenbrooke’s Cognitive Examination; H: Kruskal–Wallis test statistic; FET: Fisher’s exact test. #: Dunnet’s
pairwise analysis; ¶: out of 100; +: out of 18; §: out of 26; ƒ: out of 14; ##: out of 26; ¶¶: out of 16. Bold indicates statistically significant p-values.
Control
Cognitive 
impairment
COPD
ACE-III total score
6864605652484440 72 76
73 96
999184
86 10092.5
Cut-off score representing
possible cognitive impairment
9697
87.576
84.756962
80 84 9288 96 100
FIGURE 1 Distribution of Addenbrooke’s Cognitive Examination (ACE)-III total scores. COPD: chronic
obstructive pulmonary disease.
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therefore necessary to conduct a study to determine the pattern of cognitive impairment present in COPD.
Dementia is an umbrella term that describes a large number of diseases that have different
pathophysiological processes leading to different patterns of cognitive impairment. There are many
different types of dementia and cognitive impairment leading to very different clinical pictures; the fifth
edition of the Diagnostic and Statistical Manual of Mental Disorders [13] now refers to “major
neurocognitive disorder” in an attempt to better define conditions that have cognitive impairment as the
primary feature.
In our cross-sectional study, we included patients with known Alzheimer’s disease and compared these to
people with COPD. There were significant differences in the overall ACE-III scores and attention, memory
and fluency subscores between the COPD group and the known Alzheimer’s dementia group. These
results may suggest that the pattern of impairment in COPD was different, with our results showing that
the attention, memory and fluency domains in COPD patients was preserved compared to those with
known Alzheimer’s dementia. This adds weight to the idea that people with COPD have a different
pattern of impairment compared to those with other known causes of cognitive impairment and as such,
TABLE 4 Baseline saturations compared to overall Addenbrooke’s Cognitive Examination
(ACE)-III score and domain-specific ACE-III score (n=28)
Pearson correlation
coefficient
p-value for saturations versus overall
score and specific domains
Overall ACE-III score 0.02 0.91
Attention 0.11 0.58
Memory 0.11 0.741
Fluency −0.49 0.0067
Language 0.06 0.756
Visuospatial −0.01 0.944
Bold indicates statistically significant p-values.
TABLE 5 Forced expiratory volume in 1 s (FEV1) compared to overall Addenbrooke’s Cognitive
Examination (ACE)-III score and domain-specific ACE-III score (n=29)
Spearmann’s rank correlation
coefficient
p-value for FEV1 versus overall score and
specific domains
Overall ACE-III score −0.288 0.0651
Attention −0.282 0.069
Memory −0.363 0.0262
Fluency −0.339 0.0361
Language −0.111 0.2834
Visuospatial −0.070 0.3583
Bold indicates statistically significant p-values.
TABLE 6 Forced expiratory volume in 1 s (FEV1) % predicted compared to overall
Addenbrooke’s Cognitive Examination (ACE)-III score and domain-specific ACE-III score (n=29)
Spearmann’s rank correlation
coefficient
p-value for FEV1 % predicted versus overall
score and specific domains
Overall ACE-III score −0.109 0.282
Attention −0.1097 0.0901
Memory −0.251 0.1782
Fluency −0.114 0.2741
Language 0.1144 0.2736
Visuospatial −0.162 0.196
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COPD-associated cognitive impairment may represent a new and different type of major neurocognitive
disorder. An alternative interpretation is that in our study, those with COPD had less advanced
impairment compared to those with known Alzheimer’s dementia.
Prevalence of cognitive impairment
In people aged >65 years, dementias occur in approximately 5–8% and cognitive impairment in different
degrees in 5–20% [14]. Included studies in the review showed a range of 2–52% of COPD patients to be
affected, across age groups, although few studies used this as the specific outcome, choosing in many cases
to focus on areas of cognition instead. In our cross-sectional study, the prevalence of cognitive
impairment, as defined by the cut-off score in the ACE-III, in the COPD group was 50% (95% CI
33.8–66.3%). This prevalence rate is towards the higher end of those studies included in the review. There
is wide variation in the prevalence of cognitive impairment in COPD in the studies included in our review.
We hypothesise that the most important, likely reasons for this are the lack of consensus regarding the
definition of cognitive impairment and use of different cognitive assessment tools; even studies that used
the same cognitive tests had varying thresholds for the definition of cognitive impairment. Most
commonly used was the Mini Mental State Examination (MMSE), which was used in 14 studies; it has
been suggested that MMSE “should not be used as a diagnostic tool to identify dementia” [15] and may
underestimate impairment compared to other cognitive tests [16, 17]. The MMSE score can be affected by
age, education and cultural background [15]; studies did not always control for these factors when
interpreting scores. This underestimation of impairment with the MMSE in many of the included studies
in the review, coupled with the use of the ACE-III in our cross-sectional study, may have contributed to
the prevalence of cognitive impairment we found in COPD patients.
Domains of cognition affected in COPD
Cognitive function is classified into domains: perception, attention, memory and learning, abstract
thinking and executive function, language, and intelligence [18]. Of these, memory was the one most
consistently impaired in both the review and our validation study [1, 12, 19–21], though some studies have
reported broader deficits spanning memory, attention, symbolic representation, visual processing and
shifting capacity [22]. Neuroimaging studies [21, 23] have found reduced perfusion of frontal and
subcortical regions in COPD, possibly explaining executive dysfunction and attention deficits seen [1, 19].
Fluency was affected in our cross-sectional study; evidence from the review supported this.
From the included studies in the review, it was difficult to determine whether COPD associated with
Alzheimer’s or vascular dementia, perhaps through a confounding factor such as smoking, or was
associated with a specific pattern of cognitive impairment unique to the condition. It is known that
different areas of cognition are affected in different dementias; for example, in Alzheimer’s dementia,
memory, executive function, language, praxis and visuoconstructional abilities are primarily affected [24].
The consistent memory and fluency impairment of COPD seen in the review, and confirmed by our
cross-sectional study, may be a specific form of cognitive impairment. Cognitive impairment, particularly
in the memory and attention domains, may explain the poor adherence to inhaler therapy and health
behaviour change seen in this population [7].
Dementia is a devastating condition in terms of quality of life. COPD patients are increasingly recognised
as being at high risk for cognitive impairment and subsequent dementia. Clinically, this is important to
allow for appropriate modifications in lifestyle and drug therapies. For example, if praxic skills are
impaired in COPD, inhaled therapies would be difficult to self-administer; if verbal memory and attention
are impaired, pulmonary rehabilitation may need modifications to bring greater benefit.
Risk factors for cognitive impairment related to COPD
Patients with COPD have progressive airflow limitation and emphysematous changes in the lungs,
resulting in a ventilation–perfusion mismatch, potentially causing chronic hypoxaemia [25]. Alternatively,
the association between cognitive impairment and COPD could be explained by altered, decreased cerebral
perfusion mediated by vascular disease. There is widespread evidence suggesting hypoxaemia alone does
not account for cognitive changes seen in COPD. Studies in both inpatients and outpatients have reported
cognitive deterioration even in COPD subjects without severe hypoxaemia. In our cross-sectional study,
lower baseline saturations were significantly correlated with lower ACE-III scores in the fluency domain
but overall cognitive scores were not affected; as blood gases were not measured in our study, it is difficult
to comment on the contribution of hypoxia as a mediating factor in development of cognitive impairment.
FEV1 has been explored in relation to cognitive impairment in COPD. CLEUTJENS et al. [20] found worsening
cross-sectional memory and numeric short-term memory were associated with worsening FEV1. However,
FROHNHOFEN et al. [26] found that only 78% of their cohort and 47% of those with cognitive impairment
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could adequately complete lung function testing. Therefore, it is difficult to accurately assess any association
of cognitive impairment and FEV1 if cognitively impaired patients cannot perform spirometry. In our
cohort, lower FEV1 was significantly correlated with lower scores on the ACE-III in the domains of memory
and fluency. The mechanism for this, if unrelated to hypoxia, is not clear.
The relevance of comorbidity to cognitive impairment in COPD
Those with COPD are often smokers or ex-smokers and are older; they are likely to have significant
comorbidities [22]. In keeping with this, in the cross-sectional study, baseline differences in comorbidities
were observed between the COPD group and the control groups in CVD diagnosis and smoking history
>10 pack-years. The effect of comorbidities in COPD and cognitive dysfunction was investigated by some
of the included studies in the review. DAL NEGRO et al. [22] did not find any relationship between
cardiovascular and metabolic comorbidity and cognitive dysfunction, concluding that comorbidities were
unlikely to account for the cognitive dysfunction seen in COPD.
VILLENEUVE et al. [19] found that although patients with COPD had more vascular comorbidity, the
number and extent of vascular comorbidities was similar between the COPD patients with and without
cognitive impairment, implying that vascular comorbidities did not have a significant effect on cognition. In
our cross-sectional study, adjustments for smoking and known vascular disease were made and differences in
cognitive impairment remained. These adjustments were intended to act as a surrogate for undiagnosed
cerebrovascular disease and, whilst imperfect compared to formal diagnosis by neuroimaging, imply that the
cognitive impairment in COPD cannot be simply put down to being a cerebrovascular pathological process.
Strengths and limitations
The review augments prior work as our inclusion criteria allowed a wider overview of the research
supporting interaction between COPD and cognitive impairment, highlighting that there are mediators of
cognitive impairment that are specific to COPD, and determining key areas for future research. The
strengths and limitations of our review are discussed in the supplementary material.
A major strength of the cross-sectional study is use of the ACE-III, which is sensitive and allows
investigation of domain-specific cognitive function. Inclusion of known dementia patients was important,
as this allowed us to show the pattern of cognitive impairment in COPD was different to that in
Alzheimer’s disease.
There are a number of limitations that should be considered when interpreting the findings of the study.
This pilot study had a small sample size but despite this, shows interesting results suggesting further,
larger scale studies into this area are warranted. Patients and controls were not matched on a case by case
basis, in order to facilitate recruitment. Despite this, differences between groups were accounted for in the
analysis. We did not employ biochemical, neuroimaging or neurophysiological methods to explore the
underlying pathogenesis of cognitive impairment in patients with COPD. A larger study including people
with other types of dementia (e.g. vascular dementia or Lewy body disease) could further clarify whether
the cognitive domains affected for each type of dementia differ from the COPD group, thus giving further
evidence supporting a COPD-associated pattern of impairment. Issues with recruitment, particularly in the
established cognitively impaired population, precluded this in our centre.
We did not conduct blood gas analyses on patients involved in the study. This is a limitation as
hypercapnia and hypoxia were found to be correlated with cognitive impairment in previous studies
included in our narrative review. In further, larger studies into this area, it would be useful to conduct
blood gas analyses at the time of data collection, and investigate whether there is any association between
these and ACE-III scores.
Conclusions
The cross-sectional study demonstrates a high proportion of cognitive impairment in patients with COPD.
This is in keeping with our findings in the literature review. The cognitive domains of attention, memory
and fluency seem to be predominantly affected in our cohort. We cannot conclude that there is evidence
of a specific, discrete type of cognitive impairment unique to COPD based on the results of this
cross-sectional study and literature review alone; however, our findings further our understanding of the
pattern of cognitive impairment in patients with COPD and may help explain the poor treatment
adherence seen in this population. Further studies should seek to elucidate the underlying neurobiological
mechanisms explaining this association.
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